1,1-dimethylethyl 3-[2-cyano-6-methyl-1-(phenylmethyl)piperidin-2-yl]-3-hydroxyazetidine-1-carboxylate | 934666-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1,1-dimethylethyl 3-[2-cyano-6-methyl-1-(phenylmethyl)piperidin-2-yl]-3-hydroxyazetidine-1-carboxylate
• 英文别名: Tert-butyl 3-(1-benzyl-2-cyano-6-methylpiperidin-2-yl)-3-hydroxyazetidine-1-carboxylate
• CAS: 934666-20-3
• 化学式: C₂₂H₃₁N₃O₃
• 分子量: 385.506
• InChiKey: KLEHHOQYCLZACP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  76.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl 3-[2-cyano-6-methyl-1-(phenylmethyl)piperidin-2-yl]-3-hydroxyazetidine-1-carboxylate 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 以36%的产率得到1,1-dimethylethyl 3-hydroxy-3-[6-methyl-1-(phenylmethyl)piperidin-2-yl]azetidine-1-carboxylate
  参考文献：
  名称：

  WO2008/76415

  摘要：

  公开号：
• 作为产物：
  描述：

  1-Boc-3-氮杂环丁酮 、 6-methyl-1-(phenylmethyl)piperidine-2-carbonitrile 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.67h， 以7%的产率得到1,1-dimethylethyl 3-[2-cyano-6-methyl-1-(phenylmethyl)piperidin-2-yl]-3-hydroxyazetidine-1-carboxylate
  参考文献：
  名称：

  WO2008/76415

  摘要：

  公开号：

文献信息

• Methods of using MEK inhibitors
  申请人：Lamb Peter

  公开号：US20080166359A1

  公开（公告）日：2008-07-10

  The present invention provides methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

  本发明提供了一种通过给予I式化合物或其药学上可接受的盐或溶剂与其他癌症治疗相结合的方法来治疗癌症的方法。
• Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases
  申请人：Aay Naing

  公开号：US20100249096A1

  公开（公告）日：2010-09-30

  Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

  本发明公开了式(I)的化合物及其药学上可接受的盐和溶剂化物。这些化合物是MEK抑制剂，可用于治疗增生性疾病，如癌症。本发明还公开了含有这些化合物的制药组合物，以及使用本发明的化合物和组合物治疗癌症的方法。
• Azetidines as MEK inhibitors for the treatment of proliferative diseases
  申请人：Exelixis, Inc.

  公开号：US07803839B2

  公开（公告）日：2010-09-28

  Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

  本发明涉及式(I)化合物及其药学上可接受的盐和溶剂化物。这些化合物是MEK抑制剂，可用于治疗增殖性疾病，如癌症。本发明还涉及含有这些化合物的制药组合物，以及使用本发明的化合物和组合物治疗癌症的方法。
• MEK Inhibitors And Methods Of Their Use
  申请人：Exelixis, Inc.

  公开号：US20150141399A1

  公开（公告）日：2015-05-21

  Disclosed are compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

  本发明公开了I式化合物及其药学上可接受的盐和溶剂化物。这些化合物是MEK抑制剂，可用于治疗增殖性疾病，如癌症。本发明还公开了含有这些化合物的制药组合物，以及使用本发明的化合物和组合物治疗癌症的方法。
• US20140275527A1
  申请人：——

  公开号：——

  公开（公告）日：——